ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 613,05
0,39%
Dow Jones
43 275,91
0,09%
DAX
19 657,37
0,35%
Brent Oil
72,935
0,00%
Bitcoin
68 204,86
-0,23%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Apollomics Inc (APLM)

  7. Apollomics Inc (APLM) Actualités

APLM

Apollomics (APLM)

Apollomics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:APLM
DateHeureSourceTitreSymboleSociété
13/08/202416h50AllPennyStocks.comBiotech Sees Massive Buying Pressure Following Phase 2 Preliminary DataNASDAQ:APLMApollomics Inc
04/06/202414h00GlobeNewswire Inc.Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:APLMApollomics Inc
29/05/202414h00GlobeNewswire Inc.Apollomics Announces Presentation at the 2024 BIO International ConventionNASDAQ:APLMApollomics Inc
08/05/202422h05GlobeNewswire Inc.Apollomics Announces Private Placement Financing and Addition to Board of DirectorsNASDAQ:APLMApollomics Inc
25/04/202414h30GlobeNewswire Inc.Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneNASDAQ:APLMApollomics Inc
10/04/202413h00GlobeNewswire Inc.Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMApollomics Inc
02/04/202414h00GlobeNewswire Inc.Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMApollomics Inc
28/03/202412h00GlobeNewswire Inc.Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsNASDAQ:APLMApollomics Inc
26/03/202413h00GlobeNewswire Inc.Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024NASDAQ:APLMApollomics Inc
04/03/202413h00GlobeNewswire Inc.Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerNASDAQ:APLMApollomics Inc
07/02/202413h00GlobeNewswire Inc.Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:APLMApollomics Inc
19/01/202422h15GlobeNewswire Inc.Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:APLMApollomics Inc
17/01/202422h30GlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology ConferenceNASDAQ:APLMApollomics Inc
03/01/202413h00GlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:APLMApollomics Inc
02/01/202422h30GlobeNewswire Inc.Apollomics to Present at the 2024 Biotech ShowcaseNASDAQ:APLMApollomics Inc
04/12/202313h00GlobeNewswire Inc.Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping MutationNASDAQ:APLMApollomics Inc
29/11/202313h30GlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:APLMApollomics Inc
28/11/202313h00GlobeNewswire Inc.Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)NASDAQ:APLMApollomics Inc
16/11/202314h30GlobeNewswire Inc.Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerNASDAQ:APLMApollomics Inc
31/10/202313h30GlobeNewswire Inc.Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET DysregulationNASDAQ:APLMApollomics Inc
26/10/202314h50GlobeNewswire Inc.Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET FusionNASDAQ:APLMApollomics Inc
23/10/202314h30GlobeNewswire Inc.Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%NASDAQ:APLMApollomics Inc
17/10/202300h55GlobeNewswire Inc.Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023NASDAQ:APLMApollomics Inc
28/09/202322h17GlobeNewswire Inc.Apollomics Reports First Half 2023 Financial Results and Provides Corporate UpdateNASDAQ:APLMApollomics Inc
06/09/202313h00GlobeNewswire Inc.Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:APLMApollomics Inc
11/04/202314h30GlobeNewswire Inc.Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller SymposiumNASDAQ:APLMApollomics Inc
10/04/202315h01Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:APLMApollomics Inc
31/03/202322h01Edgar (US Regulatory)Annual Report (10-k)NASDAQ:APLMApollomics Inc
31/03/202313h40PR Newswire (US)Qiming Venture Partners Welcomes Apollomics' Successful IPO on NasdaqNASDAQ:APLMApollomics Inc
30/03/202314h00GlobeNewswire Inc.Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on NasdaqNASDAQ:APLMApollomics Inc
 Showing the most relevant articles for your search:NASDAQ:APLM

Dernières Valeurs Consultées

TG
8BTA
BriaCell Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés